From Wikipedia, the free encyclopedia
Chemical compound
Tezampanel
Routes of administration
IV
ATC code
Legal status
(3S ,4aR ,6R ,8aR )-6-[2-(1H -tetrazol-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid
CAS Number
PubChem
CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
Formula C 13 H 21 N 5 O 2
Molar mass 279.344 g·mol−1 3D model (
JSmol )
C1C[C@H]2CN[C@@H](C[C@H]2C[C@H]1CCC3=NNN=N3)C(=O)O
InChI=1S/C13H21N5O2/c19-13(20)11-6-10-5-8(1-3-9(10)7-14-11)2-4-12-15-17-18-16-12/h8-11,14H,1-7H2,(H,19,20)(H,15,16,17,18)/t8-,9+,10-,11+/m1/s1
N Key:ZXFRFPSZAKNPQQ-YTWAJWBKSA-N
N
N Y
(what is this?)
(verify)
Tezampanel (
INN ,
USAN ) (code names LY-293,558 , NGX-424 ) is a
drug originally developed by
Eli Lilly
[1] which acts as a
competitive antagonist of the
AMPA and
kainate subtypes of the
ionotropic glutamate receptor family,
[2]
[3] with selectivity for the
GluR5 subtype of the kainate receptor.
[4]
[5] It has
neuroprotective
[6] and
anticonvulsant properties,
[7] the former of which may, at least in part, occur via blockade of
calcium
uptake into
neurons .
[8]
Tezampanel has a range of effects which may be useful for
medicinal purposes , as well as its applications in
scientific research . It suppresses both the
withdrawal
symptoms from
morphine and other
opioids ,
[9]
[10]
[11] and the development of
tolerance ,
[12] as well as having
antihyperalgesic
[13] and
analgesic effects in its own right.
[14]
[15]
[16]
[17]
[18] It also has
anxiolytic effects in
animal studies and has been suggested as a candidate for the treatment of
anxiety in humans.
[19]
References
^ Gilron I (September 2001). "LY-293558. Eli Lilly & Co". Current Opinion in Investigational Drugs . 2 (9): 1273–8.
PMID
11717815 .
^ Ornstein PL, Arnold MB, Augenstein NK, Lodge D, Leander JD, Schoepp DD (July 1993). "(3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3 - carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist". Journal of Medicinal Chemistry . 36 (14): 2046–8.
doi :
10.1021/jm00066a016 .
PMID
8393116 .
^ Schoepp DD, Lodge D, Bleakman D, Leander JD, Tizzano JP, Wright RA, et al. (September 1995). "In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid". Neuropharmacology . 34 (9): 1159–68.
doi :
10.1016/0028-3908(95)00099-r .
PMID
8532186 .
S2CID
26092003 .
^ Bleakman R, Schoepp DD, Ballyk B, Bufton H, Sharpe EF, Thomas K, et al. (April 1996). "Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid". Molecular Pharmacology . 49 (4): 581–5.
PMID
8609884 .
^ Li H, Rogawski MA (1998). "GluR5 kainate receptor mediated synaptic transmission in rat basolateral amygdala in vitro". Neuropharmacology . 37 (10–11): 1279–86.
doi :
10.1016/s0028-3908(98)00109-9 .
PMID
9849665 .
S2CID
22283402 .
^ Bullock R, Graham DI, Swanson S, McCulloch J (May 1994).
"Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat" . Journal of Cerebral Blood Flow and Metabolism . 14 (3): 466–71.
doi :
10.1038/jcbfm.1994.57 .
PMID
8163588 .
^ Rogawski MA, Kurzman PS, Yamaguchi SI, Li H (2001). "Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse". Neuropharmacology . 40 (1): 28–35.
doi :
10.1016/s0028-3908(00)00112-x .
PMID
11077068 .
S2CID
1616466 .
^ Liljequist S, Cebers G, Kalda A (November 1995). "Effects of decahydroisoquinoline-3-carboxylic acid monohydrate, a novel AMPA receptor antagonist, on glutamate-induced CA2+ responses and neurotoxicity in rat cortical and cerebellar granule neurons". Biochemical Pharmacology . 50 (11): 1761–74.
doi :
10.1016/0006-2952(95)02032-2 .
PMID
8615854 .
^ Rasmussen K, Kendrick WT, Kogan JH, Aghajanian GK (November 1996).
"A selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal" . Neuropsychopharmacology . 15 (5): 497–505.
doi :
10.1016/S0893-133X(96)00094-2 .
PMID
8914123 .
^ Kest B, McLemore G, Kao B, Inturrisi CE (December 1997). "The competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist LY293558 attenuates and reverses analgesic tolerance to morphine but not to delta or kappa opioids". The Journal of Pharmacology and Experimental Therapeutics . 283 (3): 1249–55.
PMID
9400000 .
^ McLemore GL, Kest B, Inturrisi CE (December 1997).
"The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence" . Brain Research . 778 (1): 120–6.
doi :
10.1016/s0006-8993(97)00985-2 .
PMID
9462883 .
S2CID
30430984 .
^ Carlezon WA, Rasmussen K, Nestler EJ (March 1999).
"AMPA antagonist LY293558 blocks the development, without blocking the expression, of behavioral sensitization to morphine" . Synapse . 31 (4): 256–62.
doi :
10.1002/(SICI)1098-2396(19990315)31:4<256::AID-SYN3>3.0.CO;2-E .
PMID
10051106 .
S2CID
30152197 .
^ Sang CN, Hostetter MP, Gracely RH, Chappell AS, Schoepp DD, Lee G, et al. (November 1998).
"AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans" . Anesthesiology . 89 (5): 1060–7.
doi :
10.1097/00000542-199811000-00005 .
PMID
9821993 .
S2CID
34676979 .
^ Gilron I, Max MB, Lee G, Booher SL, Sang CN, Chappell AS, Dionne RA (September 2000). "Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain". Clinical Pharmacology and Therapeutics . 68 (3): 320–7.
doi :
10.1067/mcp.2000.108677 .
PMID
11014414 .
S2CID
8816761 .
^ Von Bergen NH, Subieta A, Brennan TJ (July 2002).
"Effect of intrathecal non-NMDA EAA receptor antagonist LY293558 in rats: a new class of drugs for spinal anesthesia" . Anesthesiology . 97 (1): 177–82.
doi :
10.1097/00000542-200207000-00025 .
PMID
12131120 .
S2CID
26550939 .
^ Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, et al. (July 2004). "LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine". Cephalalgia . 24 (7): 596–602.
doi :
10.1111/j.1468-2982.2004.00723.x .
PMID
15196302 .
S2CID
37366020 .
^ Lee HJ, Pogatzki-Zahn EM, Brennan TJ (October 2006).
"The effect of the AMPA/kainate receptor antagonist LY293558 in a rat model of postoperative pain" . The Journal of Pain . 7 (10): 768–77.
doi :
10.1016/j.jpain.2006.03.010 .
PMID
17018337 .
^ Jin HC, Keller AJ, Jung JK, Subieta A, Brennan TJ (October 2007).
"Epidural tezampanel, an AMPA/kainate receptor antagonist, produces postoperative analgesia in rats" . Anesthesia and Analgesia . 105 (4): 1152–9, table of contents.
doi :
10.1213/01.ane.0000281435.58012.e3 .
PMID
17898404 .
S2CID
16239521 .
^ Alt A, Weiss B, Ogden AM, Li X, Gleason SD, Calligaro DO, et al. (April 2006). "In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders". Psychopharmacology . 185 (2): 240–7.
doi :
10.1007/s00213-005-0292-0 .
PMID
16470401 .
S2CID
12559816 .
AMPAR Tooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
KAR Tooltip Kainate receptor
NMDAR Tooltip N-Methyl-D-aspartate receptor